In the pre-ADCs era, several studies have reported the discordance of HER2 status as a dichotomous variable from baseline biopsy to residual disease in patients undergoing neoadjuvant treatment, which was possibly due to tumor heterogeneity, assessment technological difference or evolution driven by treatment selection [22–24]. The gene discussed is ERBB2; the disease is neoplasm.